Cybrexa Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $40.2M

  • Investors
  • 7

Cybrexa Therapeutics General Information

Description

Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeutics rapidly bring novel compounds with robust IP to pivotal studies, enable potent drugs and combination therapies that are currently limited by toxicity, and expand the efficacy of existing anticancer agents to larger, unmet-need populations, enabling physicians to improve patient outcomes and save lives by developing the next generation of cancer therapeutics.

Contact Information

Website
www.cybrexa.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5 Science Park
  • 395 Winchester Avenue
  • New Haven, CT 06511
  • United States
+1 (860)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5 Science Park
  • 395 Winchester Avenue
  • New Haven, CT 06511
  • United States
+1 (860)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cybrexa Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 24-Jun-2022 $40.2M Completed Clinical Trials - Phase 2
6. Debt - PPP 27-Apr-2020 Completed Clinical Trials - Phase 2
5. Grant 01-Jan-2020 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B1) 20-Jun-2019 Completed Clinical Trials - Phase 2
3. Grant 01-Jan-2019 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 27-May-2017 $6.08M $6.78M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) $700K $700K Completed Startup
To view Cybrexa Therapeutics’s complete valuation and funding history, request access »

Cybrexa Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Cybrexa Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cybrexa Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeut
Drug Delivery
New Haven, CT
11 As of 2026

Rockville, MD
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cybrexa Therapeutics Competitors (38)

One of Cybrexa Therapeutics’s 38 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Kymera Therapeutics Formerly VC-backed Watertown, MA
Centrose Venture Capital-Backed Madison, WI
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 38 competitors. Get the full list »

Cybrexa Therapeutics Patents

Cybrexa Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2019136298-A1 Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues Inactive 05-Jan-2018

Cybrexa Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cybrexa Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advantage Capital (Louisiana) PE/Buyout Minority
Elm Street Ventures VC-Backed Company Minority
Singh Capital Partners Family Office Minority
Cycle Venture Partners Venture Capital Minority
National Cancer Institute Government
You’re viewing 5 of 7 investors. Get the full list »

Cybrexa Therapeutics FAQs

  • When was Cybrexa Therapeutics founded?

    Cybrexa Therapeutics was founded in 2017.

  • Where is Cybrexa Therapeutics headquartered?

    Cybrexa Therapeutics is headquartered in New Haven, CT.

  • What is the size of Cybrexa Therapeutics?

    Cybrexa Therapeutics has 11 total employees.

  • What industry is Cybrexa Therapeutics in?

    Cybrexa Therapeutics’s primary industry is Drug Delivery.

  • Is Cybrexa Therapeutics a private or public company?

    Cybrexa Therapeutics is a Private company.

  • What is Cybrexa Therapeutics’s current revenue?

    The current revenue for Cybrexa Therapeutics is .

  • How much funding has Cybrexa Therapeutics raised over time?

    Cybrexa Therapeutics has raised $47M.

  • Who are Cybrexa Therapeutics’s investors?

    Advantage Capital (Louisiana), Elm Street Ventures, Singh Capital Partners, Cycle Venture Partners, and National Cancer Institute are 5 of 7 investors who have invested in Cybrexa Therapeutics.

  • Who are Cybrexa Therapeutics’s competitors?

    Regenxbio, Genetix Biotherapeutics, Kymera Therapeutics, Centrose, and Marengo Therapeutics are some of the 38 competitors of Cybrexa Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process